Author

Lioudmila Ni

INTESTINAL ULTRASOUND RESPONSE AND TRANSMURAL REMISSION AFTER 48 WEEKS OF TREATMENT WITH USTEKINUMAB IN CROHN’S DISEASE: STARDUST TRIAL SUBSTUDY RESULTS BY LINE OF TREATMENT AND LOCATION
INTESTINAL ULTRASOUND RESPONSE AND TRANSMURAL REMISSION AFTER 48 WEEKS OF TREATMENT WITH USTEKINUMAB IN CROHN’S DISEASE: STARDUST TRIAL SUBSTUDY RESULTS BY LINE OF TREATMENT AND LOCATION

Lioudmila Ni  et al.

TREAT-TO-TARGET MAINTENANCE EFFICACY AND PHARMACOKINETICS OF USTEKINUMAB DOSING REGIMEN UP TO WEEK 48 IN THE STARDUST TRIAL
TREAT-TO-TARGET MAINTENANCE EFFICACY AND PHARMACOKINETICS OF USTEKINUMAB DOSING REGIMEN UP TO WEEK 48 IN THE STARDUST TRIAL

Lioudmila Ni  et al.

USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY-OF-LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN´S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY-OF-LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN´S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL

Lioudmila Ni  et al.

USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL

Lioudmila Ni  et al.

USTEKINUMAB DRUG EXPOSURE IS NOT LINKED TO CHANGES IN BOWEL WALL THICKNESS, BUT DOES ASSOCIATE WITH TRANSMURAL REMISSION IN CROHN’S DISEASE
USTEKINUMAB DRUG EXPOSURE IS NOT LINKED TO CHANGES IN BOWEL WALL THICKNESS, BUT DOES ASSOCIATE WITH TRANSMURAL REMISSION IN CROHN’S DISEASE

Lioudmila Ni  et al.

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE–RESPONSE RELATIONSHIPS OF USTEKINUMAB TREATMENT IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGET VS STANDARD OF CARE ANALYSIS OF THE STARDUST STUDY
PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE–RESPONSE RELATIONSHIPS OF USTEKINUMAB TREATMENT IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGET VS STANDARD OF CARE ANALYSIS OF THE STARDUST STUDY

Lioudmila Ni  et al.

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY
PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY

Lioudmila Ni  et al.

Item 1 - 7 / 7
1